Fernandes Brisa S, Hodge Jason M, Pasco Julie A, Berk Michael, Williams Lana J
IMPACT Strategic Research Centre, School of Medicine, Deakin University, PO Box 281, Geelong, VIC, 3220, Australia.
Laboratory of Calcium Binding Proteins in the Central Nervous System, Department of Biochemistry, Federal University of Rio Grande do Sul, Porto Alegre, Brazil.
Drugs Aging. 2016 Jan;33(1):21-5. doi: 10.1007/s40266-015-0323-4.
Osteoporosis is a chronic skeletal disease marked by microarchitectural deterioration of the bone matrix and depletion of bone mineral density (BMD), with a consequent increased risk for fragility fractures. It has been frequently associated with depression, which is also a chronic and debilitating disorder with high prevalence. Selective serotonin reuptake inhibitors (SSRIs), first-line agents in the pharmacological treatment of mood and anxiety disorders, have also been shown to negatively affect bone metabolism. SSRIs are the most prescribed antidepressants worldwide and a large number of persons at risk of developing osteoporosis, including older patients, will receive these antidepressants. Therefore, a proper musculoskeletal evaluation of individuals who are being targeted for or using SSRIs is a priority. The aim of this article is to review the evidence regarding the effects of depression and serotonergic antidepressants on bone and its implications for clinical care.
骨质疏松症是一种慢性骨骼疾病，其特征是骨基质微结构退化和骨矿物质密度（BMD）降低，从而导致脆性骨折风险增加。它常与抑郁症相关，抑郁症也是一种患病率高的慢性致残性疾病。选择性5-羟色胺再摄取抑制剂（SSRI）是治疗情绪和焦虑障碍的一线药物，也已被证明会对骨代谢产生负面影响。SSRI是全球处方量最多的抗抑郁药，大量有患骨质疏松症风险的人，包括老年患者，将服用这些抗抑郁药。因此，对正在接受或使用SSRI治疗的个体进行适当的肌肉骨骼评估是当务之急。本文的目的是综述关于抑郁症和5-羟色胺能抗抑郁药对骨骼的影响及其对临床护理的意义的证据。
